Journal Watch · Clinical Pharmacology & Therapeutics · 2026

Extent and Incidence of Pseudo-Worsening of Kidney Function Due to Oral Antitumor Therapeutics in the AMBORA Cohort: An Analysis of Real-World Data.

A very low rate of usage of creatinine-independent methods for assessing kidney function (cystatin C) indicates that further training of oncologists is required on OAT-induced PW to further improve patient safety.

Sponfeldner MI, Dürr P, Lensker P et al.Clinical Pharmacology & Therapeutics3 min readPharma relevance 85/100

DOI: 10.1002/cpt.70166PMID: 41427608Study type: cohort / observational clinical study

TL;DR

A very low rate of usage of creatinine-independent methods for assessing kidney function (cystatin C) indicates that further training of oncologists is required on OAT-induced PW to further improve patient safety.

Key findings

  • Cystatin C measurements were not performed in 95.8% of the patients.
  • In the group of 67 patients receiving OAT unlikely causing PW, there was no significant change in eGFR.
  • In clinical routine, multiple OAT associated with PW are prescribed.
  • A very low rate of usage of creatinine-independent methods for assessing kidney function (cystatin C) indicates that further training of oncologists is required on OAT-induced PW to further improve patient safety.

Numbers at a glance (from the abstract)

17.2%95.8%p < 0.001

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

The usage of cystatin C measurements as an alternative method for assessing kidney function was evaluated. A total of 238 patients received 38 OAT likely causing PW/with proven PW. In this group, eGFR decreased significantly (-6.8 ml/min, p < 0.001). In 17.2% of these patients, eGFR decreased by ≥20 ml/min. Significant decreases in eGFR were observed for patients receiving, for example, abemaciclib, ribociclib, and osimertinib.

Full abstract (original)

Background: A considerable number of oral antitumor therapeutics (OAT) has the potential for causing pseudo-worsening of kidney function (PW) due to inhibition of renal creatinine secretion, i.e., kidney function is unaffected, while creatinine-based calculation of glomerular filtration rate (eGFR) erroneously indicates an impaired kidney function. Nonrecognition of PW can lead to dose reductions, interruptions, or discontinuations of OAT. The extent and incidence of PW has so far not been studied for a broad set of OAT in clinical routine. In this retrospective, multicenter cohort study, 694 AMBORA patients newly started on OAT were assessed for eligibility. eGFR values were compared between baseline and within 30 days of treatment. OAT were separated into the groups unlikely causing and likely causing/with proven PW.

What they did: The usage of cystatin C measurements as an alternative method for assessing kidney function was evaluated. A total of 238 patients received 38 OAT likely causing PW/with proven PW. In this group, eGFR decreased significantly (-6.8 ml/min, p < 0.001). In 17.2% of these patients, eGFR decreased by ≥20 ml/min. Significant decreases in eGFR were observed for patients receiving, for example, abemaciclib, ribociclib, and osimertinib.

Results & conclusions: Cystatin C measurements were not performed in 95.8% of the patients. In the group of 67 patients receiving OAT unlikely causing PW, there was no significant change in eGFR. In clinical routine, multiple OAT associated with PW are prescribed. A very low rate of usage of creatinine-independent methods for assessing kidney function (cystatin C) indicates that further training of oncologists is required on OAT-induced PW to further improve patient safety.

Abstract © the authors / Clinical Pharmacology & Therapeutics (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1002/cpt.70166 · PubMed 41427608.

Why it matters for pharma & biotech

  • Directly relevant to teams in targeted oncology / immuno-oncology — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: targeted oncology / immuno-oncology

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this Clinical Pharmacology & Therapeutics study find?

A very low rate of usage of creatinine-independent methods for assessing kidney function (cystatin C) indicates that further training of oncologists is required on OAT-induced PW to further improve patient safety.

What type of study is this?

It is a cohort / observational clinical study, published in Clinical Pharmacology & Therapeutics in 2026. The usage of cystatin C measurements as an alternative method for assessing kidney function was evaluated.

Where can I read the original paper?

The original is at the publisher via DOI 10.1002/cpt.70166. PubMed ID: 41427608. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Sponfeldner MI, Dürr P, Lensker P et al.. Extent and Incidence of Pseudo-Worsening of Kidney Function Due to Oral Antitumor Therapeutics in the AMBORA Cohort: An Analysis of Real-World Data.. Clinical Pharmacology & Therapeutics (2026). DOI: 10.1002/cpt.70166.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/extent-and-incidence-of-pseudo-worsening-of-kidney-function-due-to-oral-t70166/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides